ibrutinib news

All news on ibrutinib (also known as Imbruvica): plants, production capacities, investments and involved companies.

15 July 2026

Johnson & Johnson Q2 2026 results and raises 2026 outlook

Quarterly sales topped $25.3B; adjusted net earnings and EPS rose, free cash flow improved, and full-year revenue guidance was raised above $100B for the first time.
26 June 2026

Lilly's Jaypirca recommended by CHMP for EU approval in CLL across all therapy lines

CHMP issued a positive opinion for pirtobrutinib for adults with CLL across all lines of therapy; application now referred to the European Commission for final decision.

Who will be producing ibrutinib in the future?

Find out with chemXplore Alpha

Learn more